FDA Inspections Confirm GMP Compliance at EaglePicher Pharmaceutical Services

LENEXA, Kan., Aug. 14, 2003 -- The Food and Drug Administration conducted a general, systems-based inspection of EaglePicher Pharmaceutical Services' Lenexa research facility in June 2003. The absence of any 483 observations, the form used by the FDA to communicate non- compliance and unscientific practices, confirms the high standard of GMP compliance practiced by EaglePicher Pharmaceutical Services.

In addition, the Harrisonville commercial manufacturing facility underwent both a Pre-Approval Inspection and a general inspection by the FDA in mid July. Two minor 483 observations were promptly corrected during the inspection. The FDA praised the serious commitment and positive efforts for GMP compliance at EaglePicher Pharmaceutical Services.

Critical quality systems such as documentation, the Quality Assurance program, standard operating procedures, Quality Control and material controls were subjected to the highest scrutiny by the FDA during general inspections of both facilities. The positive inspection results confirmed a strict control of the quality systems implemented by EaglePicher Pharmaceutical Services.

"These results validate the quality systems we have put in place at our facilities," said Steve Westfall, president and general manager of EaglePicher Pharmaceutical Services. "This obvious example of EaglePicher's commitment to cGMP requirements and quality systems should give our customers even more confidence in our ability to provide them the service they expect," continued Westfall. "Our customers will get the same high quality work, regardless of which facility is used."

EaglePicher Pharmaceutical Services manufactures Active Pharmaceutical Ingredients (APIs) -- including highly potent, cytotoxic compounds for anti- cancer applications -- for pharmaceutical companies worldwide. The Harrisonville facility is equipped with state of the art suites, specifically designed to ensure safe handling of potent compounds and prevent cross- contamination with other drugs.

For over thirty years, Pharmaceutical Services has also provided the industry with expert radiolabeling services to support customers' preclinical ADME studies. Radiolabeled molecules, produced by EaglePicher Pharmaceutical Services under strict cGMP compliance, are used in clinical trials. Westfall further added, "FDA inspections have confirmed the quality of work we have done to build a professional, customer-focused business at EaglePicher Pharmaceutical Services. We have the experts, experience, equipment and enthusiasm to deliver results for our customers."

Products are manufactured in strict compliance with cGMP to meet the highest standards of quality, safety and consistency. EaglePicher Pharmaceutical Services offers complete integrated contract manufacturing, process development, research and development, scale-up synthesis, analytical and regulatory affairs services throughout pre-clinical research, clinical studies, and commercialization.

EaglePicher Technologies, LLC, a wholly owned subsidiary of EaglePicher Incorporated, has facilities in Colorado, Missouri, Oklahoma, Kansas and Canada. The operating group develops and markets advanced high-reliability power systems and associated electronics for government, space and commercial applications. It also processes Boron isotopes, anticancer pharmaceutical ingredients and ultra clean scientific containers. Areas of global focus include telecommunications, medical, nuclear power plants, space, defense, environmental, semiconductors and pharmaceutical/biotech. Additional information is available on the Internet at www.eaglepicher.com .

EaglePicher Incorporated, founded in 1843 and headquartered in Phoenix, Arizona, is a diversified manufacturer and marketer of innovative, advanced technology and industrial products and services for space, defense, environmental, automotive, medical, filtration, pharmaceutical, nuclear power, semiconductor and commercial applications worldwide. The company has 4,000 employees and operates more than 30 plants in the United States, Canada, Mexico, the U.K. and Germany. Additional information on the company is available on the Internet at www.eaglepicher.com .

This news release contains statements that, to the extent that they are not recitations of historical fact, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, section 21E of the Securities Exchange Act of 1934. Such forward-looking information involves risks and uncertainties that could cause actual results to differ materially from those expressed in any such forward-looking statements. These risks and uncertainties include, but are not limited to, our ability to maintain existing relationships with customers, demand for our products, our ability to successfully implement productivity improvements and/or cost reduction initiatives; and our ability to develop, market and sell new products, our ability to obtain raw materials, increased government regulation or changing regulatory policies resulting in higher costs and/or restricting output, increased price competition, currency fluctuations, general economic conditions, acquisitions and divestitures, technological developments and changes in the competitive environment in which we operate, as well as factors discussed in our filings with the U.S. Securities and Exchange Commission.